Valbiotis

ALVALFR0013254851

RSS feed

Filings

59 filings

All Inside information59 Voting rights and capital18 Earnings release4 Share buyback4 AGM documents2

27/07/2026
VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission
Inside informationFR
22/07/2026
VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63
Inside informationFR
26/06/2026
VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
Inside informationFR
08/06/2026
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%
Inside informationFR
08/06/2026
VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East
Inside informationFR
27/05/2026
VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice
Inside informationFR
11/05/2026
VALBIOTIS SA: Valbiotis continues its expansion in Asia
Inside informationFR
23/04/2026
VALBIOTIS SA: Valbiotis expands its e-commerce to Belgium and Luxembourg
Inside informationFR
19/03/2026
VALBIOTIS SA: Valbiotis announces launch of operations in Asia
Inside informationFR
11/03/2026
VALBIOTIS SA: Valbiotis annonce la tenue de son Assemblée générale mixte des actionnaires le 17 avril 2026
Inside informationFrench
10/03/2026
VALBIOTIS SA: Valbiotis raises awareness of cardiometabolic risks with the Cœur en Jeu prevention campaign
Inside informationFR
02/03/2026
VALBIOTIS SA: 2025 Financial Results
Inside information
02/02/2026
VALBIOTIS SA: Valbiotis expands its ValbiotisPLUS® range with the new Menopause & Perimenopause solution
Inside informationFR
27/01/2026
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
Inside information
26/01/2026
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
Inside informationFR
12/01/2026
VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)
Inside informationFR
08/01/2026
VALBIOTIS SA: Valbiotis announces an exclusive distribution agreement in the Middle East
Inside informationFR
18/12/2025
VALBIOTIS SA: Valbiotis recognized by the 2025 Top Santé Award for Valbiotis Plus® Serenity, an innovative solution for emotional balance
Inside informationFR
08/12/2025
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
Inside informationFR
17/11/2025
VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Inside informationFR
09/10/2025
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
Inside information
26/06/2025
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
Inside informationFR
06/06/2025
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
Inside informationFR
22/05/2025
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
Inside informationFR
06/05/2025
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
Inside informationFR
18/04/2025
VALBIOTIS SA: Compte-rendu de l’Assemblée générale mixte du 18 avril 2025
Inside informationFrench
31/03/2025
VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
Inside informationFR
31/03/2025
VALBIOTIS SA: Valbiotis annonce la tenue de son Assemblée générale mixte des actionnaires le 18 avril 2025
Inside informationFrench
17/03/2025
VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
Inside informationFR
03/03/2025
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
Inside information
30/01/2025
VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
Inside informationFR
21/01/2025
VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
Inside informationFR
14/01/2025
VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
Inside informationFR

About

ISIN: FR0013254851
Ticker: ALVAL
LEI: 969500VP4JBJCF0MOP60
Country of registration: FR
Last filing: 27/07/2026, 17:40

Sparse profile

The AMF publishes neither sector nor description. These fields are enriched from Wikidata where a match exists.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive